News: OPT Opthea Priced IPO In U.S. Of 8.6 Million American Depositary Shares, page-3

Good article in business section of The Australian this morning. Here is an interesting quote:

"Opthea intends to retain its ASX listing, but Dr Baldwin said the NASDAQ listing will raise the company’s profile amongst US investors and biotech majors as Opthea considers whether it will bring in a partner to help develop the drug after its clinical trials are underway.

“This is a sizeable NASDAQ listing, and it’s a big one even by US standards, I believe – because a lot of the US IPOs are less than $US100m. So this will increase our profile in the US and internationally, it establishes an Australian company on the global stage,” she said.

“One of the really good points about this financing is that you can be in a stronger position by being able to move it forward independently. It means we can make the right choices and only do a partnership deal that is good – we’re not forced into a position of needing to do any one particular kind of deal, we’re independently funding through to the top-line data readout.

“That said, we’ll remain open to partnership, because we recognise you can leverage the expertise and resources of a large pharmaceutical partner.”